Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-12-05
1999-11-30
Degen, Nancy
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
435 6, 435366, 536 231, 536 245, A61K 4800, C12Q 168, C12N 512, C07H 2104
Patent
active
059943203
ABSTRACT:
The invention provides compositions and methods for treating primary brain cancer. The compositions include at least one antisense oligonucleotide that inhibits the proliferation of primary brain cancer cells. The antisense oligonucleotides are preferably complementary to and hybridize to a mRNA encoding c-myb. A method of the invention involves treating patients with primary brain cancer with a pharmaceutical composition including at least one antisense oligonucleotide in an amount effective to inhibit primary brain cell proliferation. The invention also provides probes and primers useful to identify primary brain cells having amplified and/or rearranged genes encoding c-myb.
REFERENCES:
patent: 4699877 (1987-10-01), Cline et al.
patent: 5098890 (1992-03-01), Gewirtz et al.
patent: 5585479 (1996-12-01), Hoke et al.
Rojanasakul, Antisense oligonucleotide therapeutics: drug delivery and targeting, Advanced Drug Delivery Reviews, vol. 18, pp. 115-131, 1996.
Gewirtz et al., Facilitating oligonucleotide delivery: Helping antisense deliver on its promise, Proc. Natl. Acad. Sci., vol. 93, pp. 3161-3163, Apr. 1996.
Branch, A good antisense is hard to find, TIBS, vol. 23, pp. 45-50, Feb. 1998.
Golden, Of mice and men: Don't blame the rodents, Time, vol. 151 (19), p. 44, May 18, 1998.
Baserga et al., Ann NY Acad. 660:64 (1992), Inhibition of Cell Cycle Progression by Antisense Oligodeoxynucleotides.
Behl et al., Neurosurgery 33:679 (1993), Autocrine Growth Regulation in Neuroectodermal Tumors as Detected with Oligodeoxynucleotide Antisense Molecules.
Caracciolo et al., J. of Clin. Invest. 85:55 (1990), Stage-related Proliferative Activity Determines c-myb Functional Requirements During Normal Human Hematopoiesis.
Cuddihy et al., Mol. Cell Biol. 13:3505 (1993), Only the DNA Binding and Transactivation Domains of c-myb are Required to Block Terminal Differentiation of Murine Erythroleukemia Cells.
Ferrari et al., Cell Growth and Differention 1:543 (1990), Differential Effects of c-myb and c-fes Antisense Oligodeoxynucleotides on Granulocytic Differentiation of Human Myeloid Leukemia HL60 Cells.
Grasser et al., Protein Truncation is Required for the Activation of the c-my Proto-oncogene, J. Cell Physiol. 131:43 (1987).
Iyer et al., 3H-1,2-Benzo dithiole-3-one 1,1-dioxide as an Improved Sulfurizing Reagent in the Solid Phase Synthesis of Oligodeoxyribonucleoside Phosphorothioates, J. Am. Chem. Soc. 112:1253 (1990).
Majello et al., PNAS 83:9636 (1986), Human c-myb protooncogene: Nucleotide Sequence of cDNA and Organization of the Genomic Locus.
Murphy et al., Mol. Endocrin. 6:877 (1992), Phosphorothioate Antisense Oligonucleotides Against Basic Fibroblast Growth Factor Inhibit Anchorage-dependent and Anchorage-independent Growth of a Malignant Glioblastoma Cell Line.
Nitta et al., Neurosurgery 34:309 (1994), Specific Inhibition of C-SIS Protein Synthesis and Cell Proliferation with Antisense Oligonucleotides in Human Glioma Cells.
Ku et al., J. of Biol. Chem. 268:2255 (1993), C-myb Transactivates cdc2 Expression via myb Binding Sites in the 5' Flanking Region of the Human cdc2 Gene.
Raschella et al., Cancer Res. 52:4221 (1992), Inhibition of Proliferation by C-myb Antisense RNA and Oligodeoxynucleotides in Transformed Neuroectodermal Cell Lines.
Stec et al., J. of Am. Chem. Soc. 106:6077 (1984), Automated Solid Phase Synthesis, Separation, and StereoChemistry of Phosphorothioate Analogues of Oligodeoxyribonucleotides.
Thiele et al., Mol. Cell Biol. 8:1677 (1988), Regulation of C-myb Expression in Human Neuroblastoma Cells During Retinoic Acid Induced Differentiation.
Thompson et al., Nature 319:374 (1986), Expression of the C-myb Proto-oncogene During Cellular Proliferation.
Venturelli et al., PNAS 87:5963 (1990), Inhibition of T Cell Proliferation by a MYB Antisense Oligomer is Accompanied by Selective Down Regulation of DNA Polymerase Expression.
Welter et al., Cancer Letters 52:57 (1990), The cellular myb oncogene is amplified, rearranged and activated in human glioblastoma cell lines.
Whitesell et al., PNAS 90:4665 (1993), Stability, Clearance, and Disposition of Intraventricularly Administered Oligodeoxynucleotides: Implications for Therapeutic Application within the Central Nervous System.
Anfossi et al., PNAS 86:3379 (1989), An Oligomer Complementary to C-myb-Encoded mRNA Inhibits Proliferation of Human Myeloid leukemia cell lines.
Bacon et al., Oncogene Res. 6:13 (1991), Walking Along Human c-myc mRNA with Antisense Oligodeoxynucleotides: Maximum Efficacy of the 5' Cap Region.
Brelvi et al., J. Cell Physiol. 131:43 (1987), Coordinate Expression of C-myc, C-myb and Histone H4 Genes in Reversibly Differentiating HL60 Cells.
Calabretta et al., Cancer Invest. 11:191 (1993), Functional Significance of C-myb Expression in Normal and Leukemic Hematopoiesis.
Calabretta et al., Ann. of New York Acad. of Sci. 660:117 (1992), Proto-oncogenes in the Regulation of Normal Hematopoiesis: An Antisense Approach.
Chern et al., Blood 78:991 (1991), Induction of Hemoglobin Synthesis by Downregulation of myb Protein with an Antisense Oligodeoxynucleotide.
Yoon Sang Cho-Chung, Antisense oligonucleotides for the treatment of cancer, Current Drugs Ltd ISSN, pp. 1737-1750.
Flores, et al., Society for Neuroscience Abstracts vol. 20:835 (1994), Suppression of Human Medulloblastoma Cell Proliferation with Antisense Oligonucleotides to the C-myb oncogene.
Flores, et al., Neurosurgery 35:575 (1994), Growth Inhibition of Glioma and Medulloblastoma Cells and Down Regulation of Platelet Derived Growth Factor Receptors with Antisense Oligonucleotides to C-myb oncogene.
Gewirtz et al., Ann. of New York Acad. of Sci. 660:178 (1992), Therapeutic Applications of Antisense DNA in the Treatment of Human Leukemia.
Harrison, Lancet 342:254 (1993), Antisense: into the Brain.
Helene, Eur. J. of Cancer 27:1466 (1991), Rational Design of Sequence-specific Oncogene Inhibitors Based on Antisense and Antigene Oligonucleotides.
Laske et al., Neurosurgery 80:520 (1994), Efficacy of Direct Intratumoral Therapy with Targeted Protein Toxins for Solid Human Gliomas in Nude Mice.
Milligan et al., Ann. of New York Acad. of Sci. 716:228 (1994), Development of Antisense Therapeutics: Implications for Cancer Gene Therapy.
Paoletti, Antisense Oligonucleotides as potential antitumor agents: prospective views and preliminary results, AntiCancer Drug Design 2:325 (1988).
Ramsay et al., Cell Growth and Differentiation 3:723 (1992), Myb Expression is Higher in Malignant Human Colonic Carcinoma and Pre-malignant Adenomatous Polyps than in Normal Mucosa.
Ratajczak et al., PNAS 89:11823 (1992) In Vivo Treatment of Human Leukemia in SCID Mouse Model with C-myb Antisense Oligodeoxynucleotides.
Stein et al., Science 261:1004 (1993), Antisense Oligonucleotides as Therapeutic Agents--Is the Bullet really Magical?.
Szczylik et al., Exp. Hem. 20:779 (1992), Inhibition of In Vitro Proliferation of Chronic Myelogenous Leukemia Progenitor Cells by C-myb Antisense Oligonucleotides.
Ullrich et al., Nature 309:14 (1984), Human Epidermal Growth Factor Receptor cDNA Sequence and Aberrant Expression of the Amplified Gene in A431 Epidermoid Carcinoma Cells.
Chronic Myeloid Leukemia: Potential for antisense therapy, Lancet 340:1262 (1992).
Chiang Lan
Conrad John A.
Flores Eric P.
Hall Walter A.
Low Walter C.
Degen Nancy
Regents of the University of Minnesota
Wang Andrew
LandOfFree
Antisense oligonucleotides and methods for treating central nerv does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotides and methods for treating central nerv, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotides and methods for treating central nerv will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1672702